Form 4: J&J Director Acquires Deferred Share Units

Johnson & Johnson Director Daniel E. Pinto acquired 129.058 Deferred Share Units as part of his compensation plan, increasing his total beneficial ownership to 462.069 units.

Summary

• Daniel E. Pinto, a Director of Johnson & Johnson (JNJ), acquired 129.058 Deferred Share Units (DSUs).
• The transaction occurred on March 10, 2026.
• Each DSU represents the fair market value of one share of Common Stock, valued at $242.14 for this transaction.
• These DSUs were acquired as a deferral of a cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors.
• Following this acquisition, Daniel E. Pinto beneficially owns a total of 462.069 DSUs.
• The DSUs include dividend equivalent rights and will be settled in cash upon the termination of Pinto's directorship.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a routine compensation action that aligns director interests with shareholders without indicating any significant operational changes or financial distress.

Positives

• Director Daniel E. Pinto's acquisition of Deferred Share Units aligns his interests with shareholders, as the value of DSUs is tied to the company's common stock performance.
• The use of a Deferred Fee Plan for Directors demonstrates a structured approach to executive compensation and retention.

Negatives

• No direct negative implications are apparent from this routine insider transaction filing.

Future Outlook

Deferred Share Units acquired by Director Daniel E. Pinto are expected to be settled in cash upon the termination of his directorship, with each unit representing the fair market value of one share of Common Stock on the business day prior to settlement.

Management Comments

• No direct quotes from management are provided in this Form 4 filing. The transaction itself reflects a standard compensation practice for directors.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions, particularly those related to director compensation plans like Deferred Share Units, are common across publicly traded companies in the pharmaceutical and consumer health sectors. These transactions typically reflect pre-arranged compensation structures rather than discretionary open-market purchases or sales, and are generally viewed as routine disclosures.

Comparison to Industry Standards

• The use of Deferred Share Units (DSUs) as a component of director compensation is a common practice among large, established companies, including peers in the healthcare industry such as Pfizer (PFE) and Merck (MRK), which often utilize similar equity-linked compensation vehicles to align director interests with long-term shareholder value.
• The structure, where DSUs are settled in cash upon termination of service and include dividend equivalent rights, is consistent with best practices for non-employee director compensation plans aimed at retention and long-term alignment.

Related Party Transactions

• The acquisition of Deferred Share Units by Director Daniel E. Pinto from Johnson & Johnson constitutes a related party transaction, as it involves compensation provided by the company to one of its directors under a pre-established fee plan.

Stakeholder Impact

• Shareholders: The transaction aligns the director's financial interests with those of shareholders, as the value of the DSUs is tied to the company's stock performance.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The Deferred Share Units will be settled in cash upon the termination of Daniel E. Pinto's directorship.

Key Dates

Keywords

Johnson & Johnson, JNJ, Form 4, Insider Transaction, Deferred Share Units, Director Compensation, Daniel E. Pinto, Equity Compensation